

I. Introduction

The following is a recent example of a UV-C light product <u>**not**</u> meeting "disinfection" performance expectations at a Veterans Administration (VA) hospital in Ohio:

"The **number of C-Diff rooms has increased**, despite current sanitation procedures. The Louis Stokes Cleveland VA Medical Center **currently utilizes the Tru-D Smart UVC** Part Number: 0367AOLF, but we are **still** <u>not getting the desired results</u> and the level of disinfection **expected** to especially hard to reach areas."

(1) - Louis Stokes VA Hospital, Cleveland, OH, 2017, FedBizOpps Solicitation Number: VA250-17-Q-0774.

The UV-C and PX-UV light room treatment industry is <u>not</u> regulated by any United States Government Agency. Sellers of UV-C and PX-UV light room treatment products have and are, committing <u>consumer deception</u> by <u>falsely claiming</u> that their products can "<u>disinfect</u>", "<u>sterilize</u>", or "<u>decontaminate</u>", when clearly they <u>cannot</u> as shown by the new research data further below.

The industry's assertions have been debunked by numerous independent peer-reviewed research papers, reported in key research journals, showing that UV room treatment systems do **NOT** meet the minimum Federal Government performance standards for <u>Disinfection</u>, <u>Hospital Disinfection</u>, and <u>Sterilization</u>. Even unsupported claims of <u>Decontamination</u>, are extremely serious and can impact the life, health, and safety, of the public as these claims are being relied by medical professionals to prevent injury and death.

It matters not whether the UV-C or PX-UV light is produced by Xenex, Tru-D or Clorox, they are all hampered by the same laws of physics and limitations, such as:

- Diminishing power over increasing distance
- Angle of the exposed surfaces
- Surface shadowing

Despite slick advertising and purchased studies, the fact remains, a "totally clean" or "totally disinfected" room cannot be achieved by using UV room treatment products. Failure to "disinfect" surfaces and leaving a viable pathogenic bio-burden that can infect others is not acceptable.

II. What Is <u>Disinfection</u>? And How Is the UV-C & PX-UV Industry Committing Deception?

In general, in order to claim **disinfection** a cleaning process must attain at least a **6 Log reduction** of specific organisms, in a specified period of time. **Sterilization** means a complete kill of at least 6+ Log test material leaving <u>no growth</u> on any treated surfaces.



There are different United States Government standards for claiming surface **Disinfection** and **Sterilization**. The following is very brief summary – most are time dependent:

- a) "General Disinfection" = 6 Log reduction of "Staphylococcus aureus" AND "Salmonella enterica"
- b) "Hospital Disinfection" = 6 Log reduction of "Staphylococcus aureus" AND "Pseudomonas aeruginosa"
- c) "Disinfectant with Fungicidal claims" = 6 Log reduction of "Trichophyton mentagrophytes"
- d) "Sterilant with C-Diff. Spore Claims" = 6 Log reduction of "Clostridium difficile (C. difficile) spores"

See further below: OCSPP 810.2200 (3) (2), OCSPP 810.2200 (5) & (6) (2), OCSPP 810.2200 (9)(e) (2), and OCSPPP 810.2100 (d)(2) and (g) (3).

The UV light room treatment industry should <u>NOT</u> be claiming the above performance standards unless their product(s) can meet or exceed each specific requirement. *Deceptive advertising* occurs when a claim is made, but where the product cannot actually meet the requirement(s).

The data shown further below demonstrates that both UV-C and PX-UV **cannot** meet these EPA standards.

III. Understanding Log Reduction Is Essential To Eliminating Pathogenic Risk

Hospital surfaces can be contaminated with many pathogenic bio-burden, and only achieving a *Log Reduction* at or below **6.0 Log** means dangerous viruses, bacteria, fungi, and C. difficile (C-diff) spores, can or will be left behind to proliferate and repopulate surfaces within the treated room. The literature has shown that bio-burden can be spread around to contaminate patients and/or grow new bacterial and fungal colonies on new surfaces. (**14**)

The number of bacterial survivors is very important because they can quickly increase their populations exponentially / logarithmically. For example, Staphylococcus aureus or (S. aureus) (under ideal conditions) <u>doubles</u> in 24-30 minutes (Generation Time, G), so this means 1,000 or 10^3 or *Log 3*, bacterial survivors would increase to 2,000 after 30 minutes, after 60 minutes they would increase to 4,000, and after two hours to 16,000 and then increase to over one million or 1,024,000 after 5 hours or more, if the growing environment is optimal.

IV. Examples of the Deception

Here are just a few examples from sellers of UV-C and PX-UV light room treatment products committing **consumer deception** by falsely claiming that their products can "<u>disinfect</u>" when clearly, they **cannot**.

Example # 1 – Xenex

"https://www.xenex.com/about-xenex"



"In use in more hospitals than any other **UV disinfection device**, Xenex offers the only **Pulsed Xenon UV disinfection system** on the market. Xenex Germ-Zapping Robots® are developed and designed to be highly effective, efficient and portable, allowing for the proven and **systematic disinfection of any space** within a healthcare facility." (*emphasis added*) (11)

Example # 2 - Tru-D

"http://tru-d.com/benefits/"

"Only Tru-D provides guaranteed, **total room disinfection** and has been validated by nearly all existing independent research on UVC room disinfection technology. As health care-associated infections continue to be a major threat to hospital reimbursements and the bottom line, hospital leaders must be diligent in choosing which technologies they invest in to help combat this serious problem. Proven consistent outcomes **provide a baseline of disinfection** that can only be accomplished with Tru-D's method of UVC dose measurement." (*emphasis added*) (12)


Example # 3 - Surfacide

"http://www.surfacide.com/"

"The Surfacide Helios system implements multiple emitters that allows us to **disinfect all areas** of the healthcare environments in a single cycle including the bathroom." (**13**)

"With Surfacide's three emitters operating during the same **disinfection cycle**, no exposed surface is left untouched." (*emphasis added*) (**13**)

Why UV Room Disinfection Fails:



Surface Angle to Light



V. UV light room treatment systems do <u>NOT</u> meet the above definitions as evidenced by the independent peer-reviewed research papers discussed below:

1) Michelle Nerandzic, and Curtis Donskey, MD et al.

"Evaluation Of An Automated Ultraviolet Radiation Device For Decontamination of Clostridium difficile and Other Healthcare-associated Pathogens In Hospital Rooms", <u>BioMedCentral, BMC</u> Infectious Diseases, 2010, 10:197. (8)




Figure 2 Mean reduction (log₁₀colony-forming units [CFU]/cm²) in recovery of multiple strains of *Clostridium difficile*, methicillin-resistant *Staphylococcus aureus* (MRSA), and vancomycin-resistant *Enterococcus* (VRE) from laboratory bench top surfaces after the use of the <u>Tru-D</u> device. For each pathogen, the inoculum applied to the bench top was adjusted such that 10³ to 10⁵ CFU were recovered from the positive control specimens. The Tru-D device was operated at a reflected dose of 22,000 µWs/cm² for ~45 minutes.

Comments – Figure 2: The C. difficile spore data in Figure 2 above shows a *Log Reduction* range of (2.2 to 3.1) for <u>direct UV-C light</u> exposure for <u>45 minutes</u>.

Per Federal standards, if a test surface is contaminated with 1,000,000 bacteria, and a *Log Reduction* of about 2.2 Log to 3.1 Log is obtained for C. difficile spores by exposure to <u>direct</u> <u>UV-C light</u>, that means there will still be between about less than 1,000 to almost 10,000 C. difficile spore survivors remaining. This is NOT <u>disinfection</u>, <u>decontamination</u>, or <u>sterilization</u>, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)



The MRSA (*Staphylococcus aureus*) data in Figure 2 above shows a *Log Reduction* range of (2.8 to 3.4) for <u>direct UV-C light</u> exposure.

If a test surface is contaminated with 1,000,000 bacteria, per Federal standards, and a *Log Reduction* of about 2.8 Log to 3.4 Log is shown for MRSA by exposure to <u>direct UV-C light</u>, that means there will still be between about more than 100 to more than 1,000 MRSA survivors remaining that can exponentially increase their population and constitute a health risk. This is NOT <u>disinfection</u>, <u>decontamination</u>, or <u>sterilization</u>, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)

Conclusion: This study reinforces the currently reported research data that UV-C room treatment systems, like Tru-D, do <u>NOT</u> meet the legal definitions for <u>disinfection</u>, <u>hospital</u> <u>disinfection</u>, <u>sterilization</u>, or as a <u>sporicidal</u> against C. difficle, per the United States EPA and Federal regulations. (2)(3) 2) Jennifer L. Cadnum, and Curtis Donskey, MD, et al.:

"Effect of Variation in Test methods on Performance of Ultraviolet-C Radiation Room Decontamination", <u>Infection Control & Hospital Epidemiology</u>, November 2016. (6)




FIGURE 2. Effect of inoculum dispersal on killing of *Clostridium difficile* spores and methicillin-resistant *Staphylococcus aureus* (MRSA) by the Optimum-UV Device. Steel disk carriers were inoculated with 1×10^6 colony-forming units (CFU) of the pathogens in 10 µL of phosphate-buffered saline and the inoculum was either not spread (~4-mm² area on a 10-mm² disk), spread to cover the surface area of a 10-mm² disk, or spread to cover the surface area of a 22-mm² disk. The carriers were placed <u>4 feet from</u> the device at a height of 4 feet and irradiated for 5, 10, 20, or 40 minutes. The means of data from triplicate experiments are presented. Error bars indicate standard error. Asterisk indicates P < .01 in comparison with the smaller surface area.



Comments – Figure 2: The data shown above in Figure 2 is important, because it shows the *Log Reduction* data at four (4) feet after ten (10) minutes of UV-C exposure, for bacteria that were spread over different sized disks. The *Log Reduction* data only ranged from about (0.6 - 2.0) for C. difficile spores.

Per Federal standards, when a test surface is contaminated with 1,000,000 bacteria spores, and a *Log Reduction* of about 0.6 Log to 2.0 Log is shown for C. difficile spores, between about 10,000 to 100,000+ C. difficile survivors will remain! This is NOT <u>disinfection</u>, <u>decontamination</u>, or <u>sterilization</u>. OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)

Also in Figure 2, the *Log Reduction* data ranged from about (1.0 - 5.0) for the <u>vegetative</u> <u>bacteria</u> (non-spore) MRSA (*Staphylococcus aureus*), at four (4) feet after ten (10) minutes of UV-C exposure.

Per Federal standards, when a test surface is contaminated with 1,000,000 bacteria, and a *Log Reduction* of about 1.0 Log to 5.0 Log is obtained for MRSA (*Staphylococcus aureus*), that means there will still be between about 10 to 100,000 MRSA survivors remaining that can grow their population exponentially and infect people. This is NOT <u>disinfection</u>, <u>decontamination</u>, or s<u>terilization</u>. OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)

Comments – Figure 3: As shown below in Figure 3, the test media is exposed at four (4) feet for ten (10) minutes at different orientations to the UV-C light including at: <u>zero (0) degree</u> <u>horizontal orientation</u>, forty-five (45) degree orientation, and <u>ninety (90) degree vertical</u> <u>orientation</u>. The test results show *Log Reduction* data that ranged from only about (1.3 - 2.2) for C. difficile spores depending on the test orientation. The test results also showed *Log Reduction* data that ranged from only about (3.3 – 4.8) for MRSA (*Staphylococcus aureus*) depending on the test orientation.

When a test surface is contaminated with 1,000,000 bacteria spores, and a *Log Reduction* of about 1.3 Log to 2.2 Log is shown for C. difficile spores, that means there will still be between about 1,000 to 10,000+ C. difficile survivors remaining. Pathogenic bio-burden is a health risk. When a *Log Reduction* of about 3.3 Log to 4.8 Log is obtained for MRSA, that means there will still be between about 10 to 100+ MRSA survivors remaining that can exponentially increase their population. This is <u>NOT disinfection</u>, <u>decontamination</u>, or <u>sterilization</u>, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)






FIGURE 3. Effect of orientation of the carriers relative to the ultraviolet-C lamps on killing of *Clostridium difficile* spores and methicillin-resistant *Staphylococcus aureus* (MRSA) by the Optimum-UV Device. Steel disk carriers were inoculated with 1×10^6 colony-forming units (CFU) of the pathogens in 10 µL of phosphate-buffered saline and the inoculum was spread to cover the entire 22-mm² surface area. The carriers were adhered to glass slides and positioned in parallel with the vertical lamp (ie, 90° vertical and directly facing the lamp), perpendicular to the lamp (ie, horizontal), or at a 45° angle from the lamp. The carriers were placed 4 feet from the device at a height of 4 feet and irradiated for 10 minutes. The means of data from triplicate experiments are presented. Error bars indicate standard error. Asterisk indicates P < .01 in comparison with the horizontal carriers.






FIGURE 1. Efficacy of the <u>Tru-D</u> versus <u>Clorox Healthcare Optimum-UV</u> System for killing of *Clostridium difficile* spores and methicillinresistant *Staphylococcus aureus* (MRSA). Steel disk carriers were inoculated with 1×10^6 colony-forming units (CFU) of the pathogens in 10 µL of phosphate-buffered saline and the inoculum was spread to cover the 10-mm² surface area of the disk. The carriers were placed <u>4</u> feet from the devices at a height of 4 feet and irradiated for 5, <u>10</u>, 20, or <u>40 minutes</u>. The means of data from triplicate experiments are presented. Error bars indicate standard error.

Comments – Figure 1: The data shown above in Figure 1 is important, because it shows the *Log Reduction* data at four (4) feet after ten (10) minutes, and also forty (40) minutes, of UV-C exposure, for the Tru-D UV-C product, and the Clorox Optimum UV-C product, for both MRSA bacteria and C. difficile spores.

The *Log Reduction* for C. difficile spores was about 1.7 Log for Tru-D UV-C, and 1.6 Log for Clorox UV-C, after ten (10) minutes of treatment.

Per Federal standards, when a test surface is contaminated with 1,000,000 bacteria spores, a *Log Reduction* of about 1.7 Log with Tru-D means there will be more than 10,000 C. difficile survivors remaining that can infect people, and a *Log Reduction* of about 1.6 Log with Clorox



Optimum UV-C means there will also be more than 10,000 C. difficile spores remaining that can infect people. This is NOT <u>disinfection</u>, <u>decontamination</u>, or <u>sterilization</u>, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)

The *Log Reduction* for C. difficile spores was about 3.4 Log for Tru-D UV-C, and 3.2 Log for Clorox UV-C, after <u>forty (40) minutes</u> of treatment.

Per Federal standards, when a test surface is contaminated with 1,000,000 bacteria spores, a *Log Reduction* of about 3.4 Log with Tru-D means there will be more than 100+ C. difficile survivors remaining. A *Log Reduction* of about 3.2 Log with Clorox Optimum UV-C means there will also be more than 100+ C. difficile spores remaining. This is NOT <u>disinfection</u>, <u>decontamination</u>, or <u>sterilization</u>, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)

Conclusion: First, this study demonstrates that even after <u>40 minutes</u>, both Tru-D's UV-C product, and Clorox's Optimum UV-C product, were still <u>NOT</u> able to reach a 6.0 Log performance level for either C. difficile or MRSA, and neither of these products can claim <u>disinfection</u>, <u>hospital disinfection</u>, or <u>sterilization</u>, per Federal regulations. (2)(3)

This study also reinforces the previously reported research data that UV-C light surface treatment is adversely impacted by not only the exposure time to the UV-C light source, but also the orientation or angles of the surfaces to the UV light source.

Conclusion: More importantly, per the United States EPA, these independent data show that UV-C room treatment systems do NOT meet the legal definitions for <u>disinfection</u>, <u>hospital</u> <u>disinfection</u>, <u>sterilization</u>, or as a <u>sporicidal</u> against C. difficle, per Federal regulations. (2)(3)

3) William Rutala, PhD, MPH, and David Weber, MD, MPH et al.: "*Room Decontamination with UV Radiation*", Infection Control & Hospital Epidemiology, October 2010, Vol. 31, No. 10. (7)

"The efficacy of UV irradiation is a function of many different location and operational factors, such as intensity, exposure time, lamp placement, and air movement patterns."

"In our test room, the effectiveness of UV-C radiation in reducing the counts of <u>vegetative</u> <u>bacteria on surfaces</u> was more than <u>99.9%</u> in approximately <u>15 minutes</u>, and the reduction in <u>C.</u> <u>difficile spores</u> was <u>99.8% within 50 minutes</u>."

Conclusion: According to Federal regulations, this is <u>NOT disinfection</u>, <u>decontamination</u>, or <u>sterilization</u>, that requires a 6.0 Log reduction or *Percent Reduction* of <u>99.9999%</u>, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3) The <u>99.8%</u> and <u>99.9%</u> reported percent reductions only equates to a *Log Reduction* of about 3.0 Log, leaving viable organisms.



TABLE 1. UV-C Decontamination of Formica Surfaces in Patient Rooms Experimentally Contaminated with Methicillin-Resistant *Staph*ylococcus aureus (MRSA), Vancomycin-Resistant *Enterococcus* (VRE), Multidrug-Resistant (MDR) Acinetobacter baumannii, and Clostridium difficile Spores

		UV-C line of sight						
			Total		Direct		Indirect	
Organism	Inoculum	No. of samples	Decontamination, log ₁₀ reduction, mean (95% CI)	No. of samples	Decontamination, log ₁₀ reduction, mean (95% CI)	No. of samples	Decontamination, log ₁₀ reduction, mean (95% CI)	Р
MRSA	4.88 log ₁₀	50	3.94 (2.54-5.34)	10	• 4.31 (<u>3.13–5.50</u>)	40	3.85 (2.44–5.25)	.06
VRE	4.40 log ₁₀	47	3.46 (2.16-4.81)	15	3.90 (2.99-4.81)	32	3.25 (1.97-4.62)	.003
MDR A. baumannii	4.64 log ₁₀	47	3.88 (2.59-5.16)	10	4.21 (3.27-5.15)	37	3.79 (2.47-5.10)	.07
C. difficile spores	4.12 log10	45	2.79 (1.20-4.37)	10	• 4.04 (<u>3.71–4.37</u>)	35	2.43 (<u>1.46–3.40</u>)	<.001

NOTE. Patient rooms had a mean area of 12.1 m² including bathroom. CI, confidence interval.

Comments – Table 1: The C. difficile spore data in Table 1 above shows a *Log Reduction* range of (3.71 to 4.37) for <u>direct UV-C light</u> exposure, and (1.46 to 3.40) for <u>indirect UV-C light</u> exposure.

If a test surface is contaminated with 1,000,000 bacteria, per Federal standards, and a *Log Reduction* of about 3.71 Log to 4.37 Log is achieved for C. difficile spores with exposure to <u>direct UV-C light</u>, that means there will still be between about 10 to 100+ C. difficile spore survivors remaining on surfaces. This is NOT <u>disinfection</u>, <u>decontamination</u>, or <u>sterilization</u>, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)

Also, if a test surface is contaminated with 1,000,000 bacteria, per Federal standards, and a *Log Reduction* of about 1.46 Log to 3.40 Log is achieved for C. difficile spores with exposure to indirect UV-C light, that means there will still be between about 100 to 10,000+ C. difficile spore survivors remaining on surfaces. This is NOT <u>disinfection, decontamination, or sterilization</u>, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)

The MRSA (*Staphylococcus aureus*) data in Table 1 above shows a *Log Reduction* range of (3.13 to 5.50) for <u>direct UV-C light</u> exposure, and (2.44 to 5.25) for <u>indirect UV-C light</u> exposure.

If a test surface is contaminated with 1,000,000 bacteria, per Federal standards, and a *Log Reduction* of about 3.13 Log to 5.50 Log is achieved for MRSA with exposure to <u>direct UV-C</u> <u>light</u>, that means there will still be between about 1 to 100+ MRSA survivors remaining that can exponentially increase their population and infect a person. This is NOT <u>disinfection</u>, <u>decontamination</u>, or <u>sterilization</u>, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)

If a test surface is contaminated with 1,000,000 bacteria, per Federal standards, and a *Log Reduction* of about 2.44 Log to 5.25 Log is achieved for MRSA with exposure to <u>indirect UV-C</u> <u>light</u>, that means there will still be between about 1 to 1,000+ MRSA survivors remaining that



can exponentially increase their population. This is NOT <u>disinfection, decontamination, or</u> <u>sterilization</u>, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). ⁽²⁾⁽³⁾

Conclusion: This study reinforces the current research data that UV-C light treatment process is adversely impacted by shadowed surfaces. More important, per the United States EPA and Federal regulations, this data shows that UV-C room treatment system results and claims do <u>NOT</u> meet the legal definitions for <u>disinfection</u>, <u>hospital disinfection</u>, <u>sterilization</u>, or as a <u>sporicidal</u> against C. difficle. ⁽²⁾⁽³⁾

4) John M. Boyce, MD, et al.: "Impact of Room Location on UV-C Irradiance and UV-C Dosage and Antimicrobial Effect Delivered By A Mobile UV-C Light Device", <u>Infection Control & Hospital Epidemiology</u>, June 2016, Vol. 37, NO. 6. (5)

"UV-C irradiance, UV-C dosage, and antimicrobial effect achieved in patient rooms varied significantly, depending on the location and orientation of surfaces relative to the UV-C device."

"With 15-minute cycles, counts of MRSA on disks were reduced by 3 to >4 log10 and VRE by $1-4 \log 10$ at varying distances and orientations relative to the UV-C device (Table 2). Log10 reductions of C. difficile were highest (2 to >4 log10) when disks were facing the device at a distance of 1.3 m and were lowest (0–1 log10) when disks were in a shaded area 3.3 m from the device (Table 2)." (*emphasis added*)

Comments - Referring below, to Table 2 and the data column for a <u>15 minute cycle</u> (far right), the UV-C device was NOT able to achieve even close to a 6 Log Reduction for disinfection, in <u>direct light</u> at even 1.3 meters, for vegetative bacteria like MRSA, and VRE, as well as C. difficile spores. Instead, the UV-C product achieved a <u>maximum</u> performance of only around a >4.0 Log Reduction. This is NOT <u>disinfection</u>, <u>decontamination</u>, or <u>sterilization</u>, as defined by the EPA. (2)(3)

However, more concerning was how the UV light performance was significantly degraded at even a short distance (1.3 meters) in situations where the MRSA, and VRE, as well as C. difficile spores, were exposed to the UV light at a zero (0) degree angle for a 15 minute cycle, providing a low *Log Reduction* range of only (3.0 - 4.0) for VRE, a low *Log Reduction* of only around >4.0 Log for MRSA, and a low *Log Reduction* range of only (2.0 - 4.0) for C. difficile!



TABLE 2. Range of Log₁₀ Reductions of MRSA, VRE, and *Clostridium difficile* Achieved with Inoculated Disk Carriers Exposed to UV-C for 5-Minute and 15-Minute Cycles on 3 Occasions at Each Cycle Time

Distance and Orientation of Disks Relative to UV-C Device	Mean UV-C Dosage Measured Adjacent to Disks for 5-Min Cycles, µWsec/cm ²	Range of Log ₁₀ Reduction with 5-Min Cycles, by Pathogen	Mean UV-C Dosage Measured Adjacent to Disks for 15-Min Cycles, µWsec/cm ²	Range of Log ₁₀ Reduction with <u>15-Min</u> Cycles, by Pathogen
1.3 m (4 ft), direct	342,667	MRSA: >4 log VRE: 4 to >4 log	842,000	MRSA: >4 log VRE: >4 log
		C. difficile: >2–3 log		C. difficile: 2 to $>4 \log \bullet$
1.3 m, 0° angle	53,900	MRSA: 4 to >4 log	148,667	MRSA: >4 log
		VRE: 3 to >4 log		VRE: 3-4 log
		C. difficile: 1-2 log		C. difficile: 2–4 log
1.3 m, shaded	8,547	MRSA: 1-4 log	24,467	MRSA: >4 log
		VRE: 2-3 log		VRE: 2-3 log
		C. difficile: 0		C. difficile: <u>1–2</u> log
3.3 m (10 ft), direct	67,567	MRSA: 4 to >4 log	202.667	MRSA: >4 log
		VRE: 3 to >4 log		VRE: >4 log
		C. difficile: 1–3 log		C. difficile: 2–4 log
3.3 m, 0° angle	10,767	MRSA: 4 to >4 log	29,000	MRSA: 4 to >4 log
		VRE: 2 log		VRE: 3 log
		C. difficile: 0–1 log		C. difficile: $0-2 \log =$
3.3 m, shaded	3,395	MRSA: 1–3 log	8,880	MRSA: 3 log
		VRE: 1–2 log		VRE: <u>1–2</u> log
		C. difficile: 0		C. difficile: 0–1 log

MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant Enterococcus; UV-C, ultraviolet C.

* NOTE: The data in Table 2 represents the range of "Log Reduction" data for MRSA, VRE, and Clostridium difficile (C. Difficile) spores, where the innoculated disks were placed at six (6) different locations with respect to the UV-C device: direct light, angled light at zero (0) degrees, and shaded, at two (2) different distances: 1.3 meters (4 feet) and 3.3 meters (10 feet).

Even more alarming regarding Table 2 above, is how the UV light performance was significantly degraded at even a short distance (1.3 meters) in situations where the bacteria and spores were <u>shaded</u> from the UV light for a <u>15 minute cycle</u>, providing an even lower *Log Reduction* range of only (2.0 – 3.0) for VRE, a low *Log Reduction* of only around >4.0 Log for MRSA, and an extremely low *Log Reduction* range of only (1.0 – 2.0) for C. difficile.

Finally, the UV light performance was very degraded at ten (10) feet or (3.3 meters) in situations where the bacteria and spores were <u>shaded</u> from the UV light providing an extremely low *Log Reduction* range of only (1.0 - 2.0) for VRE, a low *Log Reduction* of only around 3.0 Log for MRSA, and a shockingly low *Log Reduction* range of only (0 - 1.0) for C. difficile! When exposed to the UV light at a <u>zero (0) degree angle</u>, for a <u>15 minute cycle</u>, only a shockingly low *Log Reduction* range of (0 - 2.0) was achieved for C. difficile.

However, Cadnum and Dr. Donskey et al. (2016) (6), show that even a <u>40 minute exposure</u> <u>time</u> in the most favorable exposure orientation of facing the UV-C light (sold by Tru-D and Clorox), <u>at only 1.22 meters</u>, only provides a best case *Log Reduction* of about 5.3 Log for the <u>vegetative bacteria</u> (non-spore) MRSA (*Staphylococcus aureus*), and an even worse best case *Log Reduction* of only 3.3 Log for C. difficle spores. **Obviously, after even 40 minutes of exposure, UV-C** <u>cannot meet</u> the Federal standards for a 6.0 Log Reduction to claim **Disinfection, and UV-C** <u>cannot</u> meet the Federal Standards of "no growth" to claim efficacy for C. difficle spores.



Conclusion: The various data shown above in Table 2 and provided by Dr. Boyce et al. (2016), show that a UV-C light room treatment system is adversely impacted by surface angles, shadowing, and distance from the UV light source, and does <u>NOT</u> meet the legal definitions for <u>disinfection, hospital disinfection, sterilization</u>, or as a <u>sporicidal</u> against C. difficle, per Federal laws. ⁽²⁾⁽³⁾

5) Michelle Nerandzic, and Curtis Donskey, MD et al.: "Evaluation of a Pulsed Xenon Ultraviolet Disinfection System for Reduction of Healthcare-Associated Pathogens in Hospital Rooms", <u>Infection Control & Hospital Epidemiology</u>, February 2015, Vol. 36 No 2. (4)

"As shown in Figure 3, the efficacy of PX-UV decreased as distance from the device increased. For each pathogen, <u>significantly less reduction was achieved at 4 feet versus 6 inches and at 10</u> <u>feet versus 4 feet</u> (P < .05 for each comparison) <u>At 10 feet from the device</u>, the <u>log 10 CFU</u> <u>reduction was less than 1 log 10 CFU/cm 2 for each pathogen.</u>" (emphasis added)

"The <u>efficacy</u> of PX-UV was <u>dramatically reduced</u> as the <u>distance from the device was</u> <u>increased</u>." (emphasis added) * Important Note: PX-UV = Pulsed UV product, sold by Xenex




FIGURE 3. The effect of distance on the efficacy of the pulsed xenon ultraviolet (PX-UV) device.

The $log_{10}CFU$ reduction/cm² of *Clostridium difficile* spores, methicillinresistant *Staphylococcus aureus* (MRSA), and vancomycin-resistant *Enterococcus* (VRE) at increasing distances and shaded from the direct field of radiation delivered by the PX-UV device is shown. Carriers contained 5 $log_{10}CFU$ of each pathogen. The carriers were irradiated for <u>10 minutes</u> at a distance of <u>6</u> in, <u>4</u> feet, <u>4</u> feet shaded, and <u>10</u> ft from the PX-UV device. The means of the data from experiments conducted in triplicate are presented. Error bars indicate standard error.



Comments – Figure 3: The data shown above in Figure 3 is important, because it shows the *Log Reduction* data after ten (10) minutes of PX-UV exposure, for MRSA and VRE bacteria, and C. difficile spores, at the following distances and conditions: four (4) feet, four (4) feet (*and shaded*), and ten (10) feet.

The Log Reductions are as follows:

4 ft.	10 minutes	C. difficile spores	0.5 Log Reduction (approx.)
4 ft.	10 minutes (shaded)	C. difficile spores	0.6 Log Reduction (approx.)
10 ft.	10 minutes	C. difficile spores	0.2 Log Reduction (approx.)
4 ft.	10 minutes	MRSA	1.8 Log Reduction (approx.)
4 ft.	10 minutes (shaded)	MRSA	1.5 Log Reduction (approx.)
10 ft.	10 minutes	MRSA	0.7 Log Reduction (approx.)
4 ft.	10 minutes	VRE	0.6 Log Reduction (approx.)
4 ft.	10 minutes (shaded)	VRE	0.4 Log Reduction (approx.)
10 ft.	10 minutes	VRE	0.1 Log Reduction (approx.)


According to these data from Figure 3, the Xenex PX-UV light provided <u>extremely low</u> *Log Reductions*, and <u>NONE</u> of these *Log Reduction* values (C-diff. Spores and MRSA) are even close to meeting the Federal requirements to claim: <u>disinfection</u>, <u>hospital disinfection</u>, or <u>sterilization</u>, per the following EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3) The Xenex PX-UV light was <u>NOT</u> even able to achieve a *Log Reduction* anywhere close to the 5.0 Log amount of inoculum applied to the test slides.


Also, the Figure 3 data shows how drastically diminished the *Log Reduction* values were, when observed at a distance of ten (10) feet from the UV light source. The highest *Log Reduction* recorded was for MRSA, with a *Log Reduction* of only 0.7 Log, which is nowhere even close to the 5.0 Log amount of inoculum applied to the test slides, and certainly does <u>NOT</u> meet the EPA standards.

Comments – Figure 4: The data shown below in Figure 4 shows the low *Log Reduction* performance for <u>both</u> the <u>Xenex PX-UV light</u> product, and the <u>continuous mercury UV-C light</u> product.



4 ft.	10 minutes	C. difficile spores	1.0 Log Reduction (aprox.) - UV-C
4 ft.	10 minutes	C. difficile spores	0.5 Log Reduction (approx.) - Xenex, PX-UV
4 ft.	10 minutes	MRSA	3.1 Log Reduction (approx.) - UV-C
4 ft.	10 minutes	MRSA	1.8 Log Reduction (approx.) - Xenex, PX-UV
4 ft.	10 minutes	VRE	3.6 Log Reduction (approx.) - UV-C
4 ft.	10 minutes	VRE	0.6 Log Reduction (approx.) - Xenex, PX-UV







According to the data above from Figure 4, <u>both</u> the Xenex PX-UV light and the continuous mercury UV-C light product, <u>failed</u> to produce *Log Reduction* values (C-diff. spores <u>and MRSA</u>) that can satisfy the Federal requirements to claim: <u>disinfection</u>, <u>hospital disinfection</u>, or <u>sterilization</u>. OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)

The data shown above in Figure 4 is important, because it shows the poor *Log Reduction* data at four (4) feet after ten (10) minutes of PX-UV and UV-C light exposure. The *Log Reduction* data was reported at an extremely low *Log Reduction* of 0.5 Log for C. difficile spores by the Xenex PX-UV product, and an extremely low *Low Reduction* of 1.0 Log for C. difficile spores by the continuous mercury UV-C light product.

If a test surface is contaminated with 1,000,000 bacteria spores, and a *Log Reduction* of only 0.5 Log is obtained by Xenex PX-UV for C. difficile spores, that means more than 100,000+ C. difficile spore survivors will remain on the treated surfaces! This is NOT <u>disinfection</u>, <u>decontamination</u>, or <u>sterilization</u>, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)

In addition, the Figure 4 data shows that when a test surface is contaminated with 1,000,000 bacteria spores, and a Log Reduction of only 1.0 Log for UV-C light is achieved for C. difficile spores, that means 100,000 C. difficile spores will survive on the surface! This is NOT disinfection, decontamination, or sterilization, per the EPA standards: OCSPP 810.2200 (3), OCSPP 810.2200 (5) & (6), and OCSPPP 810.2100 (d)(2) and (g). (2)(3)

Conclusion: This study reinforces the previously reported research data that <u>both</u> the Xenex PX-UV light product, <u>and</u> the continuous mercury UV-C light product, are adversely impacted by the distance of the treated surfaces to the UV light source, and do <u>NOT</u> meet the EPA performance requirements for <u>disinfection</u>, <u>hospital disinfection</u>, <u>sterilization</u>, or as a <u>sporicidal</u> against C. difficle. (2)(3) Any claim of being able to "*disinfect an entire room*" flies in the face of this data.

6) Louis Stokes VA Hospital, Cleveland, OH, 2017, <u>FedBizOpps</u>, Solicitation Number: VA250-17-Q-0774

"The number of <u>C-Diff rooms has increased</u>, despite current sanitation procedures The Louis Stokes Cleveland VA Medical Center <u>currently utilizes the Tru-D Smart UVC</u> Part Number: 0367AOLF, but we are <u>still not getting the desired results and the level of disinfection</u> expected to especially hard to reach areas." (*emphasis added*) (1)

7) Irene Louh, MD, PhD, and Henry Ting, MD, et al.: "Clostridium Difficile Infection in Acute Care Hospitals: Systematic Review and Best Practices for Prevention", <u>Infection Control & Hospital Epidemiology</u>, April 2017, Vol. 38, NO. 4. (10)



"Terminal cleaning with UV light *in addition* to bleach cleaning had <u>uncertain efficacy</u>." (emphasis added)

"Haas et. al. instituted pulsed UV treatment *in addition* to terminal bleach disinfection in a large urban hospital, with <u>minimal incremental reduction in CDI rates</u>." (emphasis added)

8) U.S. CDC - Clinical Alert to U.S. Healthcare Facilities - June 2016, <u>U.S. Centers For Disease</u> <u>Control & Prevention</u>, "Global Emergence Of Invasive Infections Caused By The Multidrug-Resistant Yeast Candida auris", June 24, 2016 (last updated: 2017). (9)

https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html

"The Centers for Disease Control and Prevention (CDC) has received reports from international healthcare facilities that Candida auris, an emerging multidrug-resistant (MDR) yeast, is causing invasive healthcare-associated infections with <u>high mortality</u>. Some strains of C. auris have elevated minimum inhibitory concentrations (MICs) to the three major classes of antifungals, <u>severely limiting treatment options</u>." (emphasis added)

"<u>Environmental Cleaning</u> – Anecdotal reports have suggested that C. auris may persist in the environment. Healthcare facilities who have patients with C. auris infection or colonization should ensure thorough daily and terminal cleaning and <u>disinfection of these patient's rooms</u> using an EPA-registered hospital grade disinfectant with a *fungal claim*." (emphasis added)

Comment: The situation with C. auris, is a <u>serious threat to human safety</u>, and very specific standards are currently specified by the CDC, to address C. auris. <u>UV-C and PX-UV are NOT mentioned by the CDC</u> as an approved treatment to address the C. auris threat. Only *disinfectants* that can meet the United States EPA standards for hospital disinfection (OCSPP 810.2200 (5) & (6)), and fungal claims (OCSPP 810.2200 (9)(e)), are approved by the CDC to counter C. aureus.

Log Reduction	Number of cfu's	Percent Reduction
0 log (Log 0)	1,000,000	0%
1 log (Log 1)	100,000	90%
2 log (Log 2)	10,000	99%
3 log (Log 3)	1,000	99.9%
4 log (Log 4)	100	99.99%
5 log (Log 5)	10	99.999%
6 log (Log 6)	1	99.9999%



VII. UNITED STATES FEDERAL DEFINITIONS FOR DISINFECTANTS, HOSPITAL DISINFECTANTS, AND STERILANTS

a) US Legal Definition for "General Disinfection / Broad Spectrum Efficacy"

Reference: OCSPP 810.2200 (3)

DEFINITION: General or broad spectrum efficacy products - When a disinfectant is represented in labeling as having efficacy against <u>both</u> Gram-negative <u>and</u> Gram-positive bacteria, the product is considered a "general or broad spectrum" disinfectant.

According to the United States Environmental Protection Agency (EPA), "*Disinfection*" is defined as set forth in EPA Product Performance Test Guidelines, OCSPP 810.2200.

The test microorganisms are:

1) Effective against both Gram-negative and Gram-positive bacteria.

2) Staphylococcus aureus (S. aureus)(ATCC 6538) for effectiveness against Gram-positive bacteria.

3) Salmonella enterica (ATCC 10708) (S. enterica) for effectiveness against Gram-negative bacteria.

The test criteria states:

"Evaluation of confirmatory general or broad spectrum disinfectant success. The product should kill all the test microorganisms on all carriers in \leq ten minutes. In addition, per the 2009 AOAC revisions for the Use-Dilution Method, the mean log density for S. aureus is to be at least 6.0 (corresponding to a geometric mean density of 1.0 x 10^6); a mean log density <6.0 invalidates the test. For the Hard Surface Carrier Test, the dried carrier counts should be $0.5 - 2.0 \times 10^{-6}$ for Salmonella enterica and $1 - 5 \times 10^{-6}$ for Staphylococcus aureus." (emphasis added) (2)

* Summary: To meet the definition of "General Disinfection" a <u>6 log kill</u> has to be obtained for both "Staph" and "Salmonella" in <u>less than 10 minutes</u>.

b) US Legal Definition for "Hospital Disinfection"

Reference: OCSPP 810.2200 (5) & (6)



The EPA has a specific category established for the hospital and healthcare markets. For these markets, the following efficacy is required to meet the definition of disinfection as set forth in EPA Product Performance Test Guidelines, OCSPP 810.2200.

The test microorganisms are:

1) Effective against <u>both</u> Gram-negative <u>and</u> Gram-positive bacteria.

2) Staphylococcus aureus (S. aureus)(ATCC 6538) for effectiveness against Gram-positive bacteria.

3) Pseudomonas aeruginosa (P. aeruginosa)(ATCC 15442) for effectiveness against Gramnegative bacteria.

The test criteria states:

"Evaluation of confirmatory hospital or healthcare disinfectant success. <u>The product should kill</u> <u>all the test microorganisms on all carriers in \leq ten minutes</u>. In addition, per the 2009 AOAC revisions for the Use-Dilution Method, the mean log density for S. aureus and P. aeruginosa is to <u>be at least 6.0 (corresponding to a geometric mean density of 1.0 x 10^6); a mean log density</u> <u><6.0 invalidates the test</u>. For the Hard Surface Carrier Test, the dried carrier counts should be 1 –5 x 10^6 for both Staphylococcus aureus and Pseudomonas aeruginosa." (emphasis added) (2)

* Summary: To meet the definition of "Hospital Disinfection" a <u>6 log kill</u> has to be obtained for both "Staph" and "Pseudomonas" in <u>less than 10 minutes</u>.

c) US Legal Definition for "Disinfectants With Fungicidal Claims"

Reference: OCSPP 810.2200 (9)(e)

The test microorganism is:

1) Trichophyton mentagrophytes (T.mentagrophytes)(ATCC 9533)

Two samples representing two different batches of the product should be evaluated for efficacy against Trichophyton mentagrophytes (T. mentagrophytes)(ATCC 9533). The inoculum employed should provide a concentration of $\geq 5 \times 10^{6}$ conidia/mL.

Evaluation of fungicidal success. For the AOAC International Fungicidal Activity of Disinfectants test, <u>all fungal spores at 10 and 15 minutes should be killed to support a 10 minute exposure time</u>. For the AOAC International Use-Dilution Methods, *all fungal spores on <u>all 10 carriers</u>*



should be <u>killed in ≤ten minutes</u>. (emphasis added) (2)

d) US Legal Definition for "Sterilant w/ Clostridium difficile Claims"

Reference: OCSPPP 810.2100 (d)(2) and (g)

General Liquid Sterilants Claims - Mandated Log Reductions:

<u>5-6 Log</u> reduction minimum for BOTH Bacillus subtilis (B. subtilis) spores and Clostridium sporogenes (C. sporogenes) spores, AND must reach at least <u>6 Log</u> reduction minimum for Clostridium difficile (C. difficile) spores, to be classed as liquid <u>Sterilant w/ Clostridium difficile</u> (<u>C. difficile) Claims</u>. Kill everything, no growth, on ALL slides in less than XX minutes (time not specified).

The test microorganisms are:

- 1) Effective against: (B. subtilis) and (C. sporogenes) and (C. difficile)
- 2) Clostridium difficile (C. difficile) (ATCC 700792), (ATCC 43598) or (ATCC 43599)
- 3) Bacillus subtilis (B. subtilis) (ATCC 19659)
- 4) Clostridium sporogenes (C. sporogenes) (ATCC 3584)

Evaluation of sterilant success. The inoculum employed should provide a count of $1 \times 10^{-1} \times 10^{-6}$ spores per carrier. The product should <u>kill the test spores</u> on <u>all 120 carriers without any</u> <u>failures</u> (e.g., growth of test organism after carrier treatment constitutes failure). (3)

VIII. REFERENCES

1) Louis Stokes Cleveland, 2017, FedBizOpps Solicitation Number: VA250-17-Q-0774, <u>FedBizOpps</u>

2) United States Govt., https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0150-0021

3) United States Govt., https://www.regulations.gov/document?D=EPA-HQ-OPPT-2009-0150-0020

4) Michelle Nerandzic, and Curtis Donskey, MD et al.: *"Evaluation of a Pulsed Xenon Ultraviolet Disinfection System for Reduction of Healthcare-Associated Pathogens in Hospital Rooms"*, <u>Infection Control & Hospital Epidemiology</u>, February 2015, Vol. 36 No 2.



5) John M. Boyce, MD, et al.: "Impact of Room Location on UV-C Irradiance and UV-C Dosage and Antimicrobial Effect Delivered By A Mobile UV-C Light Device", Infection Control & Hospital Epidemiology, June 2016, Vol. 37, NO. 6.

6) Jennifer Cadnum, and Curtis Donskey, MD, et al.: "*Effect of Variation in Test methods on Performance of Ultraviolet-C Radiation Room Decontamination*", <u>Infection Control & Hospital Epidemiology</u>, November 2016.

7) William Rutala, PhD, MPH, and David Weber, MD, MPH et al.: "*Room Decontamination with UV Radiation*", <u>Infection Control & Hospital Epidemiology</u>, October 2010, Vol. 31, No. 10.

8) Michelle Nerandzic, and Curtis Donskey, MD et al.: "*Evaluation of an automated ultraviolet radiation device for decontamination of Clostridium difficile and other healthcare-associated pathogens in hospital rooms*", <u>BioMedCentral</u>, <u>BMC Infectious Diseases</u>, 2010, 10:197.

9) U.S. CDC - Clinical Alert to U.S. Healthcare Facilities - June 2016, <u>U.S. Centers For Disease</u> <u>Control & Prevention</u>, "*Global Emergence Of Invasive Infections Caused By The Multidrug-Resistant Yeast Candida auris*", June 24, 2016 (last updated: 2017).

10) Irene Louh, MD, PhD, and Henry Ting, MD, et al.: "*Clostridium Difficile Infection in Acute Care Hospitals: Systematic Review and Best Practices for Prevention*", <u>Infection Control & Hospital Epidemiology</u>, April 2017, Vol. 38, NO. 4.

- 11) Xenex https://www.xenex.com/about-xenex
- 12) Tru-D http://tru-d.com/benefits/
- 13) Surfacide http://www.surfacide.com/

14) Sreelatha Koganti, MD, and Curtis Donskey, MD - "Evalution of Hospital Floors as a Potential Source of Pathogen Dissemination Using a Nonpathogenic Virus as a Surrogate Marker", <u>Infection Control & Hospital Epidemiology</u>, November 2016, Vol. 37, No. 11.

Disclaimer:

Although every reasonable effort has been made to insure the accuracy of the information contained in this document, absolute accuracy cannot be guaranteed. All information are presented to the user "as is" without warranty of any kind, either express or implied. Not responsible for typographical or data errors. See EPA (<u>https://www.epa.gov/pesticides</u>) for accurate and updated information